Phase II Study of Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults With Newly Diagnosed, Standard Risk Multiple Myeloma

Trial Profile

Phase II Study of Response Adapted Therapy Using Single Agent Lenalidomide in Older Adults With Newly Diagnosed, Standard Risk Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Dexamethasone; Prednisone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2018 Planned End Date changed from 1 Dec 2019 to 1 Apr 2020.
    • 31 Jul 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Apr 2019.
    • 22 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top